gsk2126458
Solid Tumours
GlaxoSmithKlinePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
21 Active assets in the Solid Tumours cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
bh009 Zhuhai Beihai Biotech Co., Ltd | Phase 3 | B |
gw786034 Novartis Pharmaceuticals | Phase 2 | B |
gsk1120212 GlaxoSmithKline | Phase 2 | B |
Docetaxel Zhuhai Beihai Biotech Co., Ltd | Phase 3 | B |
Dabrafenib GlaxoSmithKline | Phase 2 | B |
View all 50 →
Same molecule, other indications
gsk2126458 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →